Membrane-perturbing domains of HIV type 1 glycoprotein 41

AIDS Research and Human Retroviruses

Volumn 17, Issue 4, 2001, Pages 311-327

  Mobley, P W ^a   Pilpa, R ^a   Brown, C ^b,c   Waring, A J ^b,c   Gordon, L M ^b,c  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c KING DREW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; LEUCINE ZIPPER PROTEIN; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CELL FUSION; CELL SURFACE; CIRCULAR DICHROISM; DOSE RESPONSE; ERYTHROCYTE AGGREGATION; FOURIER ANALYSIS; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SYNCYTIUM; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; CIRCULAR DICHROISM; ERYTHROCYTE AGGREGATION; ERYTHROCYTES; HEMOLYSIS; HIV ENVELOPE PROTEIN GP41; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 0035282886     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220150503681     Document Type: Article

References (93)

1. Membrane fusion
2. The role of human immunodeficiency virus type I envelope glycoproteins in virus infection
3. HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41
4. HIV-1 gp41 tertiary structure studied by EPR spectroscopy
5. Characterization of CD4-gp120 activation intermediates during human immunodeficiency virus type 1 syncytium formation
6. Atomic structure of the ectodomain from HIV-1 gp41
7. Capture of an early fusion-active conformation of HIV-1 gp41
8. HIV entry and its inhibition
9. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
10. Inhibition of human immunodeficiency virus type I infectivity by the gp41 core: Role of a conserved hydrophobic cavity in membrane fusion
11. Lipid composition and fluidity of the human immunodeficiency virus type-1
12. Thermotropic lipid phase separation in the human immunodeficiency virus
13. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
14. + cells by simian immunodeficiency virus: Productive infection associated with envelope glycoprotein-induced fusion
15. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition
16. A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation
17. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
18. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure
19. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implications for viral fusion
20. NMR and CD studies on the conformation of a synthetic peptide containing epitopes of the human immunodeficiency virus 1 transmembrane protein gp41
21. Inhibitors of human immunodeficiency virus type I derived from gp41 transmembrane protein: Structure-activity studies
22. Proline affects oligomerization of a coiled coil by inducing a kink in a long helix
23. Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1
24. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
25. Core structure of gp41 from the HIV envelope glycoprotein
26. The extracellular domain of immunodeficiency virus gp41 protein: Expression in Escherichia coli. purification and crystallization
27. Structure of influenza haemagglutinin at the pH of membrane fusion
28. A spring-loaded mechanism for the conformational change of influenza hemagglutinin
29. A syncytia assay for human immunodeficiency virus type-1 (HIV-1) envelope protein and its use in studying HIV-1 mutations
30. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41
31. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus
32. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity
33. Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion
34. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: Identification of critical glycine residues
35. 11 in the fusion peptide of HIV-1 gp41 on its function, structure and organization in membranes
36. Phospholipid interactions of synthetic peptides representing the N-terminus of HIV gp41
37. Investigation of human immunodeficiency virus fusion peptides. Analysis of interrelations between their structure and function
38. 2-terminal HIV-1 gp41 peptide in fused and aggregated liposomes
39. Interaction of the HIV-1 fusion peptide with phospholipid vesicles: Different structural requirements for fusion and leakage
40. Liposome destabilization induced by the HIV-1 fusion peptide: Effect of a single amino acid substitution
41. Fusion of negatively charged liposomes induced by peptides of the N-terminal fragment of HIV-1 transmembrane protein
42. Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: Dose and sequence effects
43. Detection of a fusion peptide sequence in the transmembrane protein of the human immunodeficiency virus
44. + lymphocytes
45. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin
46. Antivirals that target the amino-terminal domain of HIV-1 gp41
47. Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs
48. Interaction of human immunodeficiency virus (HIV-1) fusion peptide with artificial lipid membranes
49. Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer
50. Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell fusion
51. The polar region consecutive to the HIV fusion peptide participates in membrane fusion
52. The amino-terminal peptide of HIV-1 glycoprotein 41 fuses human erythrocytes
53. Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of HIV-1 transmembrane glycoprotein
54. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein gp41
55. Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain
56. Membrane fusion induced by the HIV type 1 fusion peptide: Modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds
57. The amino terminal peptide of HIV-1 glycoprotein 41 interacts with human erythrocyte membranes: Peptide conformation, orientation and aggregation
58. The amino-terminal fusion domain peptide of human immunodeficiency virus type 1 gp41 inserts into the sodium dodecyl sulfate micelle primarily as a helix was a conserved glycine at the micelle-water interface
59. The interactions of the N-terminal fusogenic peptide of HIV-1 gp41 with neutral phospholipids
60. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity
61. Effects of amino acid changes in the extracellular domain of the human immunodeficiency vires type 1 gp41 envelope glycoprotein
62. Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41
63. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type I envelope transmembrane glycoprotein
64. Interaction of the major epitope region of HIV protein gp41 with membrane model systems. A fluorescence spectroscopy study
65. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and vires infectivity
66. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of vires mediated cell-cell fusion
67. HIV-1 inhibition by a peptide
68. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 gp41 sequence
69. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41
70. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
71. Isolation and envelope sequence of a highly divergent HIV-1 isolate: Definition of a new HIV-1 group
72. Synthetic amphipathic sequences of surfactant protein-B mimic several physicochemical and in vivo properties of native pulmonary surfactant proteins
73. Conformational and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments
74. Structure and activity of protegrin-1 in model lipid membranes
75. Protein secondary structure and circular dichroism: A practical guide
76. Determination of the helix and β form of proteins in aqueous solution by circular dichroism
77. The most highly amphipathic alpha helices include two amino acid segments in human immunodeficiency virus glycoprotein gp41
78. A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41
79. The FLG motif in the N-terminal region of glucoprotein 41 of human immunodeficiency virus type 1 adopts a type-1 β in aqueous solution and serves as the initiation site for helix formation
80. Conformational mapping of a viral fusion peptide in structure-promoting solvents using circular dichroism and electrospray mass spectrometry
81. Interactions of primary amphipathic vector peptides with membranes. Conformational consequences and influence on cellular localization
82. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation
83. 13C-enhanced Fourier transform infrared spectroscopy
84. Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment
85. Fusogenic activity of amino-terminal region of HIV type 1 nef protein
86. Polymorphism and interactions of a viral fusion peptide in a compressed lipid monolayer
87. A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides
88. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immuno-deficiency virus type-1 envelope glycoprotein
89. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein
90. Interaction of the peptide fragment 828-848 of the envelope glycoprotein of human immunodeficiencv virus type 1 with lipid bilayers
91. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type I envelope glycoprotein-mediated membrane fusion
92. 13C-enhanced Fourier transfom infrared spectroscopy